Subscribe for the Newsletter

Mobile Navigation

Company Info

Impel NeuroPharma

Impel NeuroPharma

Drug Discovery & Development

Overview

Impel NeuroPharma, Inc., is a privately-held, Seattle-based biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel NeuroPharma is currently investigating INP104 (POD-DHE) for acute migraine headache, INP103 (POD-levodopa) for reversal of OFF episodes in Parkinson's disease and INP105 (POD-olanzapine) for acute agitation in schizophrenia and bipolar disorders.

Impel's products utilize its novel, nasal drug-delivery Precision Olfactory Delivery, or POD™, device technology to deliver liquid or dry powder forms of drug to the upper nasal cavity in a consistent and predictable manner. 

IMPEL, POD and the IMPEL Logo are trademarks of Impel NeuroPharma, Inc. 

Impel NeuroPharma
Contributions